The liquid biopsy-based test aims to guide patient selection and offer a noninvasive alternative to having cervical lesions removed. It will be a companion test for Inovio's VGX-3100. Qiagen's expertise in bioinformatics will boost the predictive power of Inovio's preliminary biomarker signature.